文献速递血栓与止血

免疫性血小板减少症患者的COVID-19疫苗接种

COVID-19 vaccination in patients with immune thrombocytopenia.
PubMed 文献 · Blood Adv · 2022-01-01

本研究纳入218例免疫性血小板减少症(ITP)患者和200名健康对照,比较接种COVID-19疫苗前后血小板计数变化。接种后血小板计数下降6.3%,两组下降幅度无差异。30例ITP患者(13.8%;95%CI 9.5-19.1)出现ITP加重,5例(2.2%;95%CI 0.7-5.3)发生出血事件。

要点

  • 接种后血小板计数下降6.3%,ITP患者与健康对照下降幅度无差异
  • 30例ITP患者(13.8%;95%CI 9.5-19.1)出现ITP加重
  • ITP加重的危险因素包括血小板计数<50×10⁹/L、接种时正在接受ITP治疗及年龄

核心结论

  • 本研究强调COVID-19疫苗接种在ITP患者中的安全性,以及对部分ITP患者密切监测血小板计数的重要性。
  • 出现加重的ITP患者对治疗反应良好。

研究设计与样本

  • 研究纳入218例ITP患者(50.9%女性;平均年龄55岁;中位血小板计数106×10⁹/L)和200名健康对照(60.0%女性;平均年龄58岁;中位血小板计数256×10⁹/L)。
  • 在第一次和第二次接种前即刻及接种后1周和4周采集血小板计数,采用线性混合效应模型分析血小板计数随时间的变化。

主要发现

  • 接种后血小板计数下降6.3%,两组下降幅度无差异。
  • 30例ITP患者(13.8%;95%CI 9.5-19.1)出现ITP加重,5例(2.2%;95%CI 0.7-5.3)发生出血事件。
  • ITP加重的危险因素为血小板计数<50×10⁹/L(OR 5.3;95%CI 2.1-13.7)、接种时正在接受ITP治疗(OR 3.4;95%CI 1.5-8.0)及年龄(每岁OR 0.96;95%CI 0.94-0.99)。
  • 出现加重的ITP患者对治疗反应良好。

关键数值与推荐

  • ITP加重定义为血小板计数下降≥50%,或最低血小板计数<30×10⁹/L且较基线下降>20%,或使用挽救治疗。

临床怎么用

  • 作者强调COVID-19疫苗接种在ITP患者中的安全性,以及对部分ITP患者密切监测血小板计数的重要性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder that is characterized by low platelet count and increased bleeding risk. COVID-19 vaccination has been described as a risk factor for de novo ITP, but the effects of COVID-19 vaccination in patients with ITP are unknown. We aimed to investigate the effects of COVID-19 vaccination in patients with ITP on platelet count, bleeding complications, and ITP exacerbation (≥50% decline in platelet count, or nadir platelet count < 30 × 109/L with a >20% decrease from baseline, or use of rescue therapy). Platelet counts in patients with ITP and healthy controls were collected immediately before and 1 and 4 weeks after the first and second vaccinations. Linear mixed-effects modeling was applied to analyze platelet counts over time. We included 218 patients with ITP (50.9% female; mean age, 55 years; and median platelet count, 106 × 109/L) and 200 healthy controls (60.0% female; mean age, 58 years; median platelet count, 256 × 109/L). Platelet counts decreased by 6.3% after vaccination. We did not observe any difference in decrease between the groups. Thirty patients with ITP (13.8%; 95% confidence interval [CI], 9.5-19.1) had an exacerbation and 5 (2.2%; 95% CI, 0.7-5.3) suffered from a bleeding event. Risk factors for ITP exacerbation were platelet count < 50 × 109/L (odds ratio [OR], 5.3; 95% CI, 2.1-13.7), ITP treatment at time of vaccination (OR, 3.4; 95% CI, 1.5-8.0), and age (OR, 0.96 per year; 95% CI, 0.94-0.99). Our study highlights the safety of COVID-19 vaccination in patients with ITP and the importance of the close monitoring of platelet counts in a subgroup of patients with ITP. Patients with ITP with exacerbation responded well on therapy.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Visser C, Swinkels M, van Werkhoven ED, et al. COVID-19 vaccination in patients with immune thrombocytopenia. Blood Adv. 2022. PMID: 34941989. doi:10.1182/bloodadvances.2021006379

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。